Nuvation Bio Inc Revenue Growth Rates (NUVB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Nuvation Bio Inc   (NYSE: NUVB)
 

NUVB's Revenue Growth by Quarter and Year

Nuvation Bio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NUVB/growth
https://api.csimarket.com/api/v1/companies/NUVB/fundamentals
https://api.csimarket.com/api/v1/companies/NUVB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
NUVB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 44.95
2nd Quarter June 31.69
1st Quarter March 83.23
FY 159.87





NUVB Revenue third quarter 2026 Y/Y Growth Comment
Nuvation Bio Inc reported Revenue surge of 252% year on year in the third quarter 2026, to $ 44.95 millions, this is lower than Nuvation Bio Inc 's recent average Revenue surge of 2017.56%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 18 other companies have achieved higher Revenue growth. While Nuvation Bio Inc ' s Revenue doubling of 252% ranks overall at the positon no. 71 in the third quarter 2026.


NUVB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 252 %
2nd Quarter June 643.9 %
1st Quarter March 2683.61 %
FY   -

Financial Statements
Nuvation Bio Inc 's third quarter 2026 Revenue $ 44.95 millions NUVB's Income Statement
Nuvation Bio Inc 's third quarter 2025 Revenue $ 12.77 millions Quarterly NUVB's Income Statement


NUVB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 41.85 %
2nd Quarter June -61.92 %
1st Quarter March 98.78 %
FY (Year on Year)   -


Back to NUVB Growth rate Comparisons >> Back to NUVB Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #25
Overall #71

Revenue Y/Y Growth Statistics
High Average Low
5924.06 % 2017.56 % 291.27 %
(Mar 31 2026)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #19
Healthcare Sector #25
Overall #71
Revenue Y/Y Growth Statistics
High Average Low
5924.06 % 2017.56 % 291.27 %
(Mar 31 2026)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Nuvation Bio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2963.68 % 417.03 % -80.51 %
(Dec 31 2024)  


NUVB's III. Quarter Q/Q Revenue Comment
Nuvation Bio Inc achieved in the III. Quarter 2026 below company average Revenue jump of 41.85% quarter on quarter, to $ 44.95 millions.

Within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Revenue quarter on quarter growth. While Nuvation Bio Inc 's Revenue growth quarter on quarter, overall rank is 3733.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #547
Overall #3733
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #193
Healthcare Sector #547
Overall #3733
Revenue Q/Q Growth Statistics
High Average Low
2963.68 % 417.03 % -80.51 %
(Dec 31 2024)  


NUVB's III. Quarter Q/Q Revenue Comment
Nuvation Bio Inc achieved in the III. Quarter 2026 below company average Revenue jump of 41.85% quarter on quarter, to $ 44.95 millions.

Within Major Pharmaceutical Preparations industry 192 other companies have achieved higher Revenue quarter on quarter growth. While Nuvation Bio Inc 's Revenue growth quarter on quarter, overall rank is 3733.


Nuvation Bio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 169.55
Y / Y Revenue Growth (TTM) 1115.07 %
Year on Year Revenue Growth Overall Ranking # 26
Seqeuential Revenue Change (TTM) 19.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 577


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Nuvation Bio Inc 's cumulative twelve months Revenue were $ 170 millions, company would post below average annual Revenue growth of 19.3% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Nuvation Bio Inc 's Revenue growth from the 31.69% growth in Mar 31 2026.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 17 to 26.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 10
Overall # 26

Revenue TTM Y/Y Growth Statistics
High Average Low
1217.77 %
 1166.42 %
1115.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 127
S&P 500 # 577
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Nuvation Bio Inc 's cumulative twelve months Revenue were $ 170 millions, company would post below average annual Revenue growth of 1115.07% year on year, if the fiscal year would end at Jun 30 2026.
A slow-down in the Nuvation Bio Inc 's Revenue growth from the 31.69% growth in Mar 31 2026.

Among companies within the Healthcare sector 9 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 17 to 26.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 10
Overall # 26

Revenue TTM Y/Y Growth Statistics
High Average Low
1217.77 %
1166.42 %
1115.07 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 127
S&P 500 # 577




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NUVB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions


About Nuvation Bio Inc Revenue Growth Rates (NUVB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Nuvation Bio Inc (CIK 1811063).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-447238
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Nuvation Bio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.